Clinical trials to evaluate the safety and efficacy of CXCL8-CXCR1/2 axis inhibition, as a monotherapy or as an adjunctive therapy, in specific T1D populations (i.e., by endotype, baseline disease severity) represent a critical future research direction. The gene discussed is CXCL8; the disease is type 1 diabetes mellitus.